Research progress in targeted therapy and immunotherapy for advanced adrenal cor-tical carcinoma
10.12354/j.issn.1000-8179.2024.20240823
- VernacularTitle:晚期肾上腺皮质癌靶向治疗和免疫治疗的研究进展
- Author:
Yang JINYE
1
;
Peng BO
;
Shi YUANLONG
;
Wang QIAO
;
Luo ZONGYAN
;
Zhao BIN
Author Information
1. 云南省肿瘤医院,昆明医科大学第三附属医院,北京大学肿瘤医院云南医院泌尿外科(昆明市 650118)
- Keywords:
adrenocoritical carcinoma(ACC);
targeted therapy;
immunotherapy;
combination therapy
- From:
Chinese Journal of Clinical Oncology
2024;51(16):857-861
- CountryChina
- Language:Chinese
-
Abstract:
Adrenocortical carcinoma(ACC)is the most prevalent malignant tumor of the adrenal gland and is characterized by a poor pro-gnosis in its advanced stages.Surgical resection of the tumors is typically limited to patients diagnosed in the clinical stages Ⅰ and Ⅱ,lead-ing to a high postoperative recurrence rate.The combination of mitotane(M)with etoposide(E),doxorubicin(D),and cisplatin(P)(EDP-M)is currently the only approved first-line treatment regimen for advanced ACC.However,the efficacy of chemotherapy and radiation therapy in ACC remains limited.If the EDP-M regimen proves ineffective,there are no standardized or universally accepted second-line systemic treat-ment alternatives.Research advancements in the molecular mechanisms of ACC in recent years has led to increasing investigations on tyr-osine kinase inhibitors(TKIs)targeting EGFR,VEGFR,and mTOR,as well as immune checkpoint inhibitors(ICIs).Moreover,previous studies have identified mutations in CTNBB1,TP53,KDM5A,CENP-H,and other genes that may serve as therapeutic targets or biomarkers,thereby expanding the treatment options available for ACC.ICIs are effective against diverse cancer types,including non-small cell lung cancer(NSCLC),liver cancer,renal cell cancer,and urothelial cancer.Ongoing exploration into targeted therapies and immunotherapy,especially combination treatments,holds the promise of extending the survival of patients and enhancing their quality of life.
